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ABSTRACT 
Introduction   UK dual diagnosis (co-occurrence of substance use and mental health 
problems) prevalence data is limited to specific regions and reported rates vary 
widely. Reliable information on actual service provision for dual diagnosis clients has 
not been collated. Thus a national survey was carried out to estimate dual diagnosis 
prevalence in treatment populations and describe the service provision available for 
this client population in drug/alcohol (DAS) and mental health services (MHS). 
Design   A questionnaire was sent to managers of 706 DAS and 2374 MHS. Overall, 
249 (39%) DAS and 493 (23%) MHS participated in the survey. 
Results   In both DAS and MHS, around 32% of clients were estimated to have dual 
diagnosis problems. However, less than 50% of services reported assessing clients 
for both problem areas. Regarding specific treatment approaches, most services 
(DAS: 88%, MHS: 87%) indicated working jointly with other agencies. Significantly 
fewer services used joint protocols (DAS: 55%, MHS: 48%) or shared care 
arrangements including access to external drug/alcohol or mental health teams 
(DAS: 47%, MHS: 54%). Only 25% of DAS and 17% of MHS employed dual 
diagnosis specialists. 
Conclusions   Dual diagnosis clients constitute a substantial proportion of clients in 
both DAS and MHS in England. Despite recent policy initiatives, joint working 
approaches tend to remain unstructured.  
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INTRODUCTION 
Dual diagnosis (co-occurrence of mental health and substance misuse problems) has 
attracted significant research attention. Whilst most studies in the field stem from the 
US [e.g. 1-4], there is a growing contribution from other countries including Australia 
[5], Canada [6], Norway [7] and UK [8-11]. Studies show that dual diagnosis (DD) is 
frequently associated with poorer treatment outcomes [12-17], and the effectiveness 
of different treatment approaches has recently come under investigation [18-21].  
 
Prevalence data is often limited to small geographical regions. Due to widely varying 
rates found, it remains difficult to estimate the actual scale of the problem among 
treatment populations. In the UK, studies have predominantly focused on the severe 
mentally ill treated in psychiatric settings [8-9, 22-23] and report DD rates ranging 
from five to 68%. An overview of studies (Table 1) provides estimates of lifetime 
and/or current prevalence of substance misuse. The highest prevalence rate (68%) 
was found in a study which, unlike most other studies, assessed lifetime substance 
use rather than misuse/dependence. The lowest rate (5%) was found in a study of 
current non-alcohol substance misuse in psychotic in-patients [24], however other 
studies report considerably higher current prevalence rates. For instance, Menezes 
et al. [9] reported a current substance misuse rate of 36% in a similar setting. A 
possible explanation for this discrepancy may be the difference in time-thresholds: In 
Duke et al.’s [24] study ‘current’ misuse was defined as ‘in the previous month’ whilst 
most other studies used a six- to 12-month timeframe. Within studies using the six- to 
12-month definition, more homogeneous DD prevalences of between 20 to 33% were 
reported [25-28].  
 
Insert Table 1  
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Several studies extended their investigation from mental health settings to 
drug/alcohol services [27-28] and found that DD relating to severe mental illness also 
appears to be a problem in addiction services (see Table 2). 
 
Insert Table 2  
 
Further evidence is contributed by studies which include DAS clients with less severe 
mental illness. For instance, a large UK study [29] found that 20% of drug treatment 
clients had previously received psychiatric treatment and 15 to 33% indicated high 
levels of psychiatric symptoms at treatment intake. This study investigated DD in 
different treatment settings thus minimizing the risk of selection bias. However, 
compared to other studies the DD prevalence rate is quite low. For instance Weaver 
and colleagues [30] found that 75% of DAS clients screened positively for at least 
one psychiatric disorder. Even higher proportions were revealed by another study 
[31] that demonstrated a preliminary rate of 93% reducing to 83% after full 
assessment.  
 
Few studies examined DD in MHS with the focus on non-psychotic clients. Overall, 
prevalence rates ranged from two to 44%, with the highest proportions in community 
mental health teams [30-32]. A study on clients treated for post-traumatic stress 
disorder found a very low prevalence of drug abuse disorder (2%, [33]). However, a 
further 19% of participants reported drinking over recommended limits and another 
19% used drugs. This is of importance as previous research has shown that even 
small amounts of drugs/alcohol can be harmful for the mentally ill [34].  
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When comparing DD prevalence rates across studies we need to bear in mind 
methodological differences between studies. In particular, previous reports have 
highlighted the effect of inconsistent approaches regarding assessment tools, client 
selection bias, differences in the geographical context and particularly the use of 
different DD definitions [11, 35-36]. Depending on clinical thresholds, different client 
populations have been included or excluded; hence samples often represent 
somewhat different DD subgroups.  
 
It is now widely recognized that DD clients may fall between existing specialist 
services which tend to focus on treating one or the other problem [37-40]. This has 
led to different strategies and approaches. For example, US services have been 
shown to be effective in providing more integrated support for DD clients [41]. In the 
UK, where service provision is in many respects very different [42], policy guidelines 
emerged aiming to address treatment shortcomings by improving joint working 
between agencies [43]. Additionally, a recent UK drug treatment framework [44] 
explicitly includes treatment options for DD clients. The three major approaches 
regarding DD treatment are referred to as sequential, parallel and integrated 
treatment (for detailed information see 43, 45-47]. Integrated treatment (focusing on 
both problem domains simultaneously) is currently favoured as the most promising 
approach [37, 49-50]. 
 
So far, little is known about the extent to which the UK guidelines have been 
implemented [51]. Furthermore, evidence for the effectiveness for any specific 
treatment approach is inconsistent [18, 20-21, 52]. In practice, there are likely to be 
variations of service provision that fall somewhere between integrated and standard 
treatment, for example due to limited resources to deliver focused treatment [48]. 
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However, our understanding of the DD-related treatment offered across services is 
inadequate. Therefore, as part of a larger study on DD treatment pathways, a 
national survey was carried out a) to obtain information about DD prevalence 
throughout DAS and MHS in England and b) to describe the nature and extent of DD 
provision currently available.  
 
METHODS 
 
Procedure 
A questionnaire was sent to managers of all adult DAS and MHS in England. As 
treatment delivery was a topic of the survey, DAS providing only information/advice 
were excluded. DAS were identified by searching electronic databases and existing 
directories [53-56]. No comprehensive national MHS directory was available. Thus, 
services were identified from NHS Trust websites and local directories.  
 
Managers were asked to define DD broadly, i.e. to include severe and less severe 
mental health problems and varying degrees of substance misuse. The survey was 
sent to 706 DAS and 2374 MHS in early 2006. The services had four weeks to 
respond. Non-respondents were sent a reminder including an additional 
questionnaire. All letters contained addressed pre-paid return envelopes. 
 
Instrument 
We developed a three-paged questionnaire, which comprised twelve multiple-
response questions and four open-ended questions. The first section asked about 
service type and treatment setting (see Table 3) and was used to split services into 
two groups: DD+ (accepting DD clients) and DD- (not accepting DD clients). Only 
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DD+ services completed the remainder of the questionnaire. Information was 
obtained about the service’s total number of clients, proportion of DD clients, DD 
treatment approaches, and about clients’ referral pathways, psychiatric disorders and 
substance use. Services were also asked about their staff including their 
qualifications. Four open-ended questions invited managers to express their views 
about treatment access routes for DD clients, satisfaction with existing joint working 
arrangements and information exchange between services. 
 
Analyses 
Statistical analyses were performed using SPSS [57]. Chi-square tests were applied 
for categorical data. Additional non-parametric tests were conducted as appropriate. 
The qualitative part of the questionnaire was analysed using content analysis [58].  
 
Response rate 
Drug/alcohol services (DAS) 
Twenty-nine services indicated that the survey was not applicable to them. Thirty-
nine questionnaires failed to reach services probably due to closure of service or 
changed location. Thus, 638 services remained and of these 249 (39%) responded. 
 
Mental health services (MHS) 
Overall, 131 services returned the questionnaire uncompleted and 53 questionnaires 
failed to reach the addressee. Thus, 2190 services remained and 493 (23%) 
completed forms were returned. 
 
Information about agency type was obtained for the 389 DAS and 1686 MHS non-
respondents. In both service groups, statutory services were less likely to have 
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responded than non-statutory (χ²(1)=11.19, p<0.01 and χ²(1)=9.86, p<0.01, 
respectively).  
 
RESULTS 
 
Sample characteristics 
Drug/alcohol services (DAS) 
Of the 249 DAS, 75% described themselves as drug & alcohol service, 21% as drug 
only service and 5% as alcohol only service, see Table 3. Most offered traditional 
community-based treatment (70%), followed by open access (57%) and residential 
treatment (44%, several services spanned two categories). Overall, 65 (26%) 
respondents reported not to accept DD clients (DD-).  
 
Insert Table 3 here 
 
Mental health services (MHS) 
Of the 493 MHS, 82% were statutory. Access & crisis services were most common 
(28%), followed by outpatient clinical services and continuing care services (19% 
each). Overall, 144 (29%) respondents described themselves as DD-. 
 
Dual diagnosis prevalence 
The data in the following sections apply to DD+ only. In DAS, the average number of 
clients treated in the past year was 640 of which one third (33%) were identified as 
dually diagnosed. DD prevalence rates did not differ by service types (χ²(2)=1.85, 
p>0.05). 
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In MHS, the average number of clients treated was 364 and again one third (32%) 
were estimated to have co-morbid problems. The highest prevalence of DD was 
found in secure services (62%), followed by services for mentally ill offenders (45%), 
continuing care services (34%) and finally accommodation services (24%, 
χ²(8)=26.68, p<0.01).  
 
Additionally, we asked whether the information provided was based on the 
respondents’ estimates or on service databases. Only a minority reported systematic 
collation of DD data (DAS: 18%, MHS: 25%, χ²(1)=2.27, p>0.05) with most services 
relying on estimates. 
 
Dual diagnosis assessments 
The answer as to why there is incomplete recording of DD may lie in services’ 
assessment procedures. Less than half of DAS and an even smaller proportion of 
MHS reported undertaking assessments for both substance use and mental health 
problems (46% vs. 37%, χ²(1)=3.65, p>0.05).  
 
Inter-agency work 
The majority indicated working jointly with other agencies (DAS: 88%, MHS: 87%). 
However, fewer services used joint protocols (DAS: 55%, MHS: 48%, χ2(1)=2.44, 
p>0.05) or shared care arrangements including access to external DAS/MHS (DAS: 
47%, MHS: 54%, χ2(1)=1.79, p>0.05; see Table 5). Twenty-three percent of DAS and 
32% of MHS indicated joint working but without having joint protocols or shared care 
arrangements in place (χ2(1)=0.30, p>0.05). All three approaches were confirmed by 
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one third of MHS and 37% of DAS (χ2(1)=6.18, p>0.05). Only few services reported 
not to use any of them (DAS: 11%, MHS: 10%) 
 
Insert Table 4 here. 
 
There is a marked discrepancy between the reports of 90% of services indicating 
joint-working and substantially lower proportions of services using all three 
recommended approaches (DAS: 37%, MHS: 33%). It remains unclear how inter-
agency work can be managed without appropriate tools such as shared protocols, 
and with limited access to other teams.  
 
Further analysis revealed that services were more likely to treat DD clients in a 
sequential rather than parallel manner. Overall, 49% of DAS reported referring clients 
with psychiatric problems to a MHS before treatment at their own service, and 
similarly, 55% of MHS (χ²(1)=1.39, p>0.05) initially referred their clients to DAS. The 
most common approach was to transfer clients to a DAS/MHS after treatment 
provision at their own service (83% each). However by looking at combinations within 
services, overlapping patterns were found. That is, 50% of MHS and similar 
proportions of DAS (46%, χ²(1)=1.01, p>0.05) indicated to do both, referring DD 
clients before and after treatment at their service, compared to a minority which 
reported to do neither (DAS: 14%, MHS: 13%, χ²(1)=0.01, p>0.05).  
 
In contrast, more than half of DAS and almost two thirds of MHS also reported to 
provide simultaneous treatment for both drug/alcohol and mental health problems 
through their own team (54% vs. 65%, χ²(1)=5.41, p<0.05). However, by looking at 
job qualifications among staff, it emerges that only few services employed DD 
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specialists (ie professionals with special training/accredited DD expertise, DAS: 25%, 
MHS: 17%, χ²(1)=4.60, p<0.05). Furthermore, information about mental health 
qualifications in DAS and addiction qualifications in MHS was obtained. Overall, 51% 
of DAS had at least one mental health nurse or psychologist or psychiatrist in their 
team. In comparison, only 8% of MHS employed at least one drug/alcohol worker. 
 
Descriptive accounts obtained by the open-ended questions echoed obstacles 
regarding inter-agency work. Most DAS respondents (68%) and 36% of MHS 
reported that services tend to focus merely on the drug/alcohol or the mental health 
aspect which often results in referring DD clients from one service to another. This 
set of problems was often described by terms such as ‘buck-passing’, ‘ping-pong 
effect’ and ‘chicken-egg debates’. Recognising this, respondents also pointed out 
that joint working arrangements urgently need to be improved (DAS: 84%, MHS: 
50%). Aspects which were most frequently mentioned in this context were joint 
assessments, joint care plans and joint protocols. Overall there was a great 
emphasis on the lack of communication between services.  
 
DISCUSSION 
For the first time, information about DD prevalence was obtained from DAS and MHS 
on a national level. The survey demonstrated that co-morbidity appears to be of 
concern in both service groups as DD problems were identified in about 32% of 
clients. This figure falls into the mid-range of previous findings in the UK where 
widely varying estimates ranging from two to 68% in MHS and four to 83% in DAS 
were reported [22-23, 31, 36, 59-60]. Similarly, our findings fit well with recent non-
UK studies, which reported prevalence rates ranging from six to 78% in the US [61-
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63], 34 to 51% in Norway [7], 14 to 45% in Canada [6], 29% to 43% in Germany [64] 
and 27 to 49% in Spain [65] across different treatment settings. 
 
The obtained prevalence rates may be underestimates as our findings suggest that 
many services may fail to identify DD because no comprehensive assessments are 
undertaken with new clients. In more than 50% of services clients were not assessed 
for co-morbid problems and the vast majority of services did not systematically 
collate data on the level of DD problems in their clientele. Such findings carry 
important implications in terms of service planning. By not recognising DD problems 
early, clients’ needs may not be appropriately met, possibly resulting in less favorable 
outcomes including high drop out rates [35, 66].  
 
Overall, the observation that over a quarter of the sample did not accept DD clients 
echoes the widely discussed problem of treatment exclusion in relation to co-morbid 
clients, despite guidelines to streamline DD service provision and thereby improve 
treatment options [44-45]. 
 
By looking at the distribution of agency types, it was found that residential DAS 
appeared to be more likely to exclude DD clients compared to other DAS types and 
similarly, continuing care MHS seemed to be less likely to treat DD clients. 
Residential DAS and continuing care MHS provide long-term treatment with the 
majority of services requiring clients to be drug free at treatment intake. However, DD 
clients may face greater obstacles in seeking to achieve abstinence [67] and 
therefore may often not be accepted at such services. This shortfall of treatment 
availability stands in contrast to current recommendations to provide long-term 
support as in DD clients, positive outcomes are less likely to be achieved by brief 
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interventions [68-69]. Hence such findings may prompt questions about the extent to 
which service eligibility criteria are tailored towards DD clients.  
 
An interesting picture was generated regarding the current level of inter-agency work. 
On the one hand, almost 90% of services indicated joint working with other agencies. 
On the other hand, such liaisons appeared to lack joint protocols and access to other 
teams in a substantial proportion of the sample. Thus although joint working 
approaches have been encouraged, practical experience suggests there are still 
difficulties to be overcome in bringing about collaboration across agencies. Appleby’s 
report [51] pointed out that only a minority of services had implemented local liaisons 
to enhance DD service provision and this would still appear to be the case as only a 
third of respondents confirmed arrangements of all three recommended approaches 
in terms of inter-agency work. However, it is encouraging that in only few services 
none of the approaches was used. Thus it is likely that liaisons are currently in the 
development stage, however lacking consistency across services. This observation 
was further supported by responses to the open-ended questions where the majority 
of respondents highlighted difficulties in coordinating inter-agency work and 
underlined the need to improve such liaisons.  
 
Probably as a result of these difficulties, it was found that most respondents treat DD 
clients sequentially, although this approach was identified as being of less benefit for 
people with co-morbidity [11].  
 
The recurrent question is how such joint working problems can be best addressed. 
Whilst current UK policy documents outline frameworks on how to proceed with DD 
clients, there appear to remain a variety of practical problems. This was also 
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recognised by the Department of Health prompting the publication of a new policy 
report [70] to provide further guidance. However this guide focuses on MHS only, 
whilst further support for DAS appears to be equally relevant. 
 
In addition to difficulties in service provision, DD clients have often been described as 
being ‘the most complex cases’ and practitioners report feeling powerless to deal 
with them [71]. This is important in light of our findings that only a minority of services 
employed DD specialists (DAS: 25%, MHS: 17%). Instead, services that do provide 
simultaneous treatment mainly rely on existing staff skills to address both mental 
health and substance misuse problems.  
 
Given the high vulnerability of co-morbid clients there is a risk that clients do not 
receive adequate treatment and that at the same time practitioners are 
overstretched. Therefore it is of great importance to develop strategies to improve 
joint working, increase the number of staff from both the substance misuse and 
mental health field across services and/or provide DD training programmes for 
existing staff [72-74]. 
 
Our findings need to be considered in the light of a low response rate, especially from 
MHS (23%) which is particularly dissapointing as the former are to take the lead in 
DD service provision [43]. 
 
Another limitation was that most services relied on estimates of DD prevalence in 
their caseloads. This carries two important implications: firstly it highlights the need to 
improve standardised assessment and recording procedures and secondly it 
weakens data reliability.  
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There is the possibility of a degree of response style bias associated with social 
desirability, ie some managers may have avoided highlighting shortfalls in their 
services. As the survey was addressed to managers rather than practitioners, 
responses may not always have reflected actual practice. This viewpoint was 
supported by regional DD leads who expressed doubts about the high rates of joint 
working, and indicated that results may reflect the managers’ expectations of what 
their services ‘ought to do’ rather than actual practice (personal conversation, 
5/9/2006).  
 
However, the essential strength of the survey is that, for the first time, the same 
instrument was applied throughout DAS and MHS on a national level. This enables 
comparisons in a consistent manner between the two settings, which has not hitherto 
been possible.  
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Table 1: Overview DD prevalence studies across mental health treatment settings in England 
 
Author (year) Location N¹ Problem areas  DD prevalence Prevalence timeframe 
 
Mathers et al. (1991) London 640  Alcohol problems and mental illness 28%  Lifetime 
Duke et al. (1994) Westminster 271 Alcohol problems and SMI only²  22%  Lifetime 
Menezes et al. (1996) London  171  Drug/alcohol problems and SMI only 36%  Previous 12 months 
Holland (1999)  Manchester 225   Drug/alcohol problems and SMI only 27%   Previous 6 months 
Wright et al. (2000)  London  40  Drug/alcohol problems and SMI only 33%   Previous 6 months 
Graham et al. (2001)  Birmingham 1369³  Drug/alcohol dependence and SMI only 20%   Previous 12 months 
Virgo et al. (2001) Dorset 708  Drug/alcohol abuse and SMI only 18%  Previous 6 months 
Weaver et al. (2003) 4 inner-city areas 282  Drug/alcohol problems and mental illness 44%  Previous 12 months 
Duke et al. (2001)  Westminster 265  Non-alcohol misuse and SMI only  5% / 22% Previous month / lifetime 
Strathdee et al. (2002) London 323          20%   
      59  Drug/alcohol problems and mental illness  43%  Previous 12 months 
      29         56%   
Ley et al. (2002)   Devon 112   Drug use and mental illness   23%  At time of assessment only 
Phillips et al. (2003)  London 264   Drug/alcohol misuse and SMI only   49%  Previous 6 months 
Tarrier et al. (2003)  North West  120   Alcohol abuse disorder and PTSD only   7%  
       Hazardous alcohol use and PTSD only  19%  At time of assessment 
    Drug abuse disorder and PTSD only  2%  
      Hazardous drug use and PTSD only  19%  
Barnes et al. (2006) London 152  Alcohol misuse and SMI only   27%  Lifetime 
     Substance use and SMI only   35% / 68% Previous month / lifetime 
¹ Study population 
² Refers to whether or not a study focused on clients with severe mental illnesses only (SMI only) 
³ The number provided represents the whole study sample including clients recruited from substance misuse services 
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Table 2: Overview DD prevalence studies across drug/alcohol treatment settings in England 
 
Author (year)  Location N¹  Problem areas DD prevalence Prevalence timeframe 
 
Marsden et al. (2000)  Across England 1075  Drug/alcohol problems and psychiatric treatment 20%  Previous 24 months 
Weaver et al.  (2003)   4 inner-city areas 278  Drug/alcohol problems and mental illness 75%  Previous 12 months 
Virgo et al. (2001)   Dorset 313  Drug/alcohol abuse and SMI only² 22% / 12% Previous 6 months / lifetime 
Graham et al. (2001)   Birmingham 1369³ Drug/alcohol dependence and SMI only  4%  Previous 12 months 
Strathdee et al. (2002)  London  74  Drug/alcohol problems and mental illness  83%  Previous 12 months 
¹ Study population 
² Refers to whether or not a study focused on clients with severe mental illnesses only (SMI only) 
³ The number provided represents the whole study sample including clients recruited from mental health services 
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Table 3: Service profiles and percentage of services offering the following treatments (n, %) 
 
Drug/alcohol services 
 DD+ DD- All services χ2 
 (n=184) (n=65) (N=249) 
 
Statutory 62 (40%)  8 (16%) 70 (34%) 9.35** 
Non-statutory 94 (60%) 42 (84%) 136 (66%) 9.35** 
 
Drug & alcohol service 130 (73%) 50 (79%) 180 (75%) 0.94 
Drug only service 37 (21%) 13 (21%) 50 (21%) 0.00 
Alcohol only service 11 (  6%) N/A  11 (  5%) 4.06* 
 
Open access treatment 117 (63%) 25 (39%) 142 (57%) 12.04** 
Community- based treatment 152 (82%) 22 (34%) 174 (70%) 53.07** 
Residential treatment 65 (35%) 44 (68%) 109 (44%) 20.73** 
 
 
Mental health services 
 DD+ DD- All services χ2 
 (n=349) (n=144) (N=493) 
 
Statutory 288 (88%) 76 (66%) 364 (82%) 26.55** 
Non-statutory 41 (12%) 39 (34%)  81 (18%)   26.04** 
 
Access & crisis service 121 (35%) 14 (10%) 135 (28%)  28.74** 
Secure service 20 (  6%)  5 (  4%)  25 (  5%)    0.82 
Therapy service 47 (14%) 33 (25%)  80 (17%)    8.48** 
Service for mentally ill offenders 33 (10%)  2 (  2%)  35 (  7%)    9.25** 
Accommodation service 15 (  4%)  6 (  5%)  21 (  4%)    0.01 
Clinical service – inpatient 60 (17%) 12 (  9%)  72 (15%)    5.33* 
Clinical service – outpatient 70 (20%) 19 (14%)  89 (19%)    2.34 
Continuing care service 54 (16%) 37 (28%)  91 (19%)    9.06** 
Home care service 27 (  8%)  7 (  5%)  34 (  7%)    0.98 
Carers’ service 17 (  5%)  2 (  2%)  19 (  4%)    2.97 
* p<0.05 (2-tailed) 
** p<0.01 (2-tailed) 
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Table 4: Inter-agency work across DAS and MHS (n, %) 
 
DAS MHS χ2 
 
Joint working with other agencies 155 (88%) 281 (88%) 0.03 
Joint protocols 92 (55%) 149 (48%) 2.44 
Access to external teams 81 (47%) 165 (54%) 1.79 
Client referral before treatment 84 (49%) 176 (55%) 1.39 
Client referral after treatment 142 (83%) 263 (83%) 0.01 
Simultaneous treatment by own staff 92 (54%) 206 (65%) 5.17* 
* p<0.05 (2-tailed) 
** p<0.01 (2-tailed) 
